Antares Pharma, Inc.
ATRS
ATRS was delisted on the 23rd of May, 2022.
120 hedge funds and large institutions have $181M invested in Antares Pharma, Inc. in 2018 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 37 increasing their positions, 33 reducing their positions, and 10 closing their positions.
150% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 10
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
14% more funds holding
Funds holding: 105 → 120 (+15)
12% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 33
8% less capital invested
Capital invested by funds: $197M → $181M (-$16.6M)
58% less call options, than puts
Call options by funds: $632K | Put options by funds: $1.49M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$3.89M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$3.42M |
| 3 |
Millennium Management
New York
|
+$2.69M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.87M |
| 5 |
FI
Fosun International
Hong Kong,
China
|
+$1.78M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$3.88M |
| 2 |
JP Morgan Chase
New York
|
-$2.98M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.29M |
| 4 |
MWP
MYCIO Wealth Partners
Philadelphia,
Pennsylvania
|
-$863K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$465K |
ATRS Hedge Fund Activity: Q4 2018 in Review
120 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Antares Pharma, Inc. (ATRS) for Q4 2018, worth a combined $181M — down 8.4% from $197M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new ATRS positions and 10 closed out — a net gain of 15 holders — while 37 added to existing stakes and 33 trimmed.
The largest buyer was Armistice Capital, adding an estimated $3.89M. The largest seller was Broadfin Capital, cutting an estimated $3.88M.
- 120 institutional investors held Antares Pharma, Inc. (ATRS) as of Q4 2018, up from 105 in Q3 2018.
- Funds reported $181M of Antares Pharma, Inc. stock for Q4 2018, down 8.4% quarter-over-quarter.
- 25 funds opened new Antares Pharma, Inc. positions in Q4 2018 and 10 closed out, a net change of +15 holders.
- The largest Antares Pharma, Inc. buyer in Q4 2018 was Armistice Capital, an estimated $3.89M added.
- The largest Antares Pharma, Inc. seller in Q4 2018 was Broadfin Capital, an estimated $3.88M sold.
Based on aggregated 13F filings for Q4 2018.